Preceptorship Programme

Colorectal Cancer

ESMO Preceptorship

MEXICO CITY MEXICO
24-25 MARCH 2022

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:
Dirk Arnold, Germany
Rachel Riechelmann, Brazil
Erika Ruiz-Garcia, Mexico
ESMO PRECEPTORSHIP PROGRAMME
COLORECTAL CANCER
Multidisciplinary management, standards of care and future perspectives

Mexico City, Mexico
24-25 March 2022

CO-CHAIRS: Dirk Arnold, Germany
Rachel Riechelmann, Brazil
Erika Ruíz-Garcia, Mexico

SPEAKERS: Horacio Astudillo, Mexico
David Huitzil, Mexico
Juan Manuel O’Connor, Argentina
Lino Silva, Mexico
Laura Torrecillas, Mexico
Itzel Vela, Mexico

LEARNING OBJECTIVES

• To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
• To understand the importance of pathology and histo-prognostic factors
• To learn about the management of patients after progression, side-effects of treatments and in special situations

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:45</td>
<td>Welcome and introduction</td>
<td>Chairs: Dirk Arnold, DE</td>
</tr>
<tr>
<td>08:45-10:05</td>
<td>SESSION 1 Early colorectal cancer</td>
<td>Chairs: Dirk Arnold, DE</td>
</tr>
<tr>
<td>10:05-10:35</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>10:35-12:15</td>
<td>SESSION 2 Metastatic colorectal cancer: About decision making</td>
<td>Chairs: Erika Ruiz-Garcia, MX</td>
</tr>
<tr>
<td>12:15-13:30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13:30-15:25</td>
<td>SESSION 3 Special clinical situations</td>
<td>Chairs: Juan Manuel O’Connor, AR</td>
</tr>
<tr>
<td>15:25-16:00</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION 1 Early colorectal cancer**

- The point of view of the pathologist: Quality and rules of a good pathology report - Histo-pathological relevant factors
  - Lino Silva, MX
- Managing rectal cancer: Patient selection, and multimodal treatment strategies, and goals: From “limited” to “total”.
  - Dirk Arnold, DE
- The role of systemic therapy in rectal cancer: (Neo)adjuvant procedures. The view of a Medical Oncologist
  - Laura Torrecillas, MX
- Optimal surgery in rectal cancer: Why meso-rectal surgical resection is better? Minimal invasive surgery is safe in rectum?
  - Itzel Vela, MX

**SESSION 2 Metastatic colorectal cancer: About decision making**

- How to select the best 1st line treatment?
  - Rachel Riechelmann, BR
- Oligometastatic colorectal cancer: Understanding disease basics and treatment decisions
  - Dirk Arnold, DE
- Oligometastatic colorectal cancer: How to optimally treat limited metastatic disease?
  - David Huitzil, MX
- Clinical cases: An expert real case from speakers
  - All chairs

**SESSION 3 Special clinical situations**

- Treatment of patient progressing after 1st line and beyond
  - Rachel Riechelmann, BR
- Molecular subtypes of advanced colon cancer: RAS- and BRAF mutant, HER2, and others: What can we do?
  - Erika Ruiz-Garcia, MX
- Circulating tumour DNA (ctDNA) in colorectal cancer: Status quo further perspectives
  - Dirk Arnold, DE
- Participants clinical case discussion (3x15’)
  - Faculty
<table>
<thead>
<tr>
<th>16:00-18:20 140’</th>
<th>SESSION 4</th>
<th>Adjuvant settings of colorectal cancer</th>
<th>Chairs: Erika Ruíz-Garcia, MX Dirk Arnold, DE</th>
</tr>
</thead>
<tbody>
<tr>
<td>30’</td>
<td>Molecular markers in localized disease</td>
<td>Horacio Astudillo, MX</td>
<td></td>
</tr>
<tr>
<td>15’</td>
<td>Adjuvant treatment strategies for stage II colon cancer: Tailoring the benefit</td>
<td>Juan Manuel O’Connor, AR</td>
<td></td>
</tr>
<tr>
<td>15’</td>
<td>Adjuvant Chemotherapy for stage III colon cancer: To whom, and how?</td>
<td>Juan Manuel O’Connor, AR</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Early onset colorectal cancer and the implications in clinical practice</td>
<td>Erika Ruíz-Garcia, MX</td>
<td></td>
</tr>
<tr>
<td>60’</td>
<td>Participants clinical case discussion (4x15’): Localized, colon and rectal cancer</td>
<td>Faculty</td>
<td></td>
</tr>
</tbody>
</table>

| 20:30 | Dinner |

---

**Friday, 25 March 2022**

<table>
<thead>
<tr>
<th>08:30-10:40 130’</th>
<th>SESSION 5</th>
<th>Metastatic colorectal cancer: Special clinical cases</th>
<th>Chairs: Dirk Arnold, DE Erika Ruíz-Garcia, MX</th>
</tr>
</thead>
<tbody>
<tr>
<td>15’</td>
<td>Maintenance treatment: What to do, after induction?</td>
<td>Dirk Arnold, DE</td>
<td></td>
</tr>
<tr>
<td>30’</td>
<td>Immunotherapy in colorectal cancer: Where are we? And how will this field evolve?</td>
<td>Rachel Riechelmann, BR</td>
<td></td>
</tr>
<tr>
<td>25’</td>
<td>Treatment of side effects</td>
<td>Erika Ruíz-Garcia, MX</td>
<td></td>
</tr>
<tr>
<td>60’</td>
<td>Participants clinical case discussion (4x15’)</td>
<td>Faculty</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10’</td>
<td>Closing and final remarks</td>
<td>Dirk Arnold, DE Erika Ruíz-Garcia, MX Rachel Riechelmann, BR</td>
</tr>
</tbody>
</table>

**Note:** Each 15-minute slot for clinical case discussion includes 7’ case presentation and 8’ Q&A / panel discussion.